These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24342415)

  • 1. Successful treatment of a patient with symptomatic long QT syndrome type 3 using ranolazine combined with a beta-blocker.
    van den Berg MP; van den Heuvel F; van Tintelen JP; Volders PG; van Gelder IC
    Int J Cardiol; 2014 Jan; 171(1):90-2. PubMed ID: 24342415
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of ranolazine in long-QT syndrome type 3.
    Kaufman ES
    J Cardiovasc Electrophysiol; 2008 Dec; 19(12):1294-5. PubMed ID: 18662183
    [No Abstract]   [Full Text] [Related]  

  • 3. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome.
    Moss AJ; Zareba W; Schwarz KQ; Rosero S; McNitt S; Robinson JL
    J Cardiovasc Electrophysiol; 2008 Dec; 19(12):1289-93. PubMed ID: 18662191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serious QT interval prolongation with ranolazine and amiodarone.
    Tarapués M; Cereza G; Arellano AL; Montané E; Figueras A
    Int J Cardiol; 2014 Mar; 172(1):e60-1. PubMed ID: 24424337
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome.
    Wu L; Shryock JC; Song Y; Li Y; Antzelevitch C; Belardinelli L
    J Pharmacol Exp Ther; 2004 Aug; 310(2):599-605. PubMed ID: 15031300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of beta-blocker therapy on ventricular repolarization documented by 24-h electrocardiography in patients with type 1 long-QT syndrome.
    Viitasalo M; Oikarinen L; Swan H; Väänänen H; Järvenpää J; Hietanen H; Karjalainen J; Toivonen L
    J Am Coll Cardiol; 2006 Aug; 48(4):747-53. PubMed ID: 16904544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8).
    Shah DP; Baez-Escudero JL; Weisberg IL; Beshai JF; Burke MC
    Pacing Clin Electrophysiol; 2012 Mar; 35(3):e62-4. PubMed ID: 20883512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.
    Chorin E; Hu D; Antzelevitch C; Hochstadt A; Belardinelli L; Zeltser D; Barajas-Martinez H; Rozovski U; Rosso R; Adler A; Benhorin J; Viskin S
    Circ Arrhythm Electrophysiol; 2016 Oct; 9(10):. PubMed ID: 27733495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with ranolazine in a veteran population with chronic stable angina.
    Reeder DN; Gillette MA; Franck AJ; Frohnapple DJ
    Ann Pharmacother; 2012 Jan; 46(1):42-50. PubMed ID: 22215689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination use of ranolazine with dofetilide for the maintenance of atrial fibrillation.
    Shah SA; Koyama G; Da Costa D; McGregor P; Kolasa M
    Int J Cardiol; 2014 Apr; 172(3):e428-9. PubMed ID: 24461967
    [No Abstract]   [Full Text] [Related]  

  • 11. Inherited long QT syndrome: phenotype and therapy to use and avoid.
    Conti CR
    Clin Cardiol; 2006 Oct; 29(10):429-30. PubMed ID: 17063944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranolazine-induced Repolarization Changes: A Case Report.
    Kumthekar A; Cossarini F; Shih JC; Taub CC; Massera D
    Am J Med; 2015 Jul; 128(7):e3-5. PubMed ID: 25660248
    [No Abstract]   [Full Text] [Related]  

  • 13. Ranolazine (Ranexa) for chronic stable angina.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Jun; (99):1-6. PubMed ID: 17595750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of late sodium current by mexiletine: a novel pharmotherapeutical approach in timothy syndrome.
    Gao Y; Xue X; Hu D; Liu W; Yuan Y; Sun H; Li L; Timothy KW; Zhang L; Li C; Yan GX
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):614-22. PubMed ID: 23580742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long QT syndrome].
    Abrams DJ; Perkin MA; Skinner JR
    Praxis (Bern 1994); 2010 Jul; 99(14):854-8. PubMed ID: 20607668
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of change in posture and exercise on repolarization in patients with long QT syndrome with HERG channel mutations.
    Walker BD; Krahn AD; Klein GJ; Skanes AC; Yee R; Wang J; Hegele RA
    Can J Cardiol; 2005 Jan; 21(1):33-8. PubMed ID: 15685300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
    Melloni C; Newby LK
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial.
    Sendón JL; Lee S; Cheng ML; Ben-Yehuda O;
    Eur J Prev Cardiol; 2012 Oct; 19(5):952-9. PubMed ID: 22689417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?
    Ackerman MJ; Priori SG; Dubin AM; Kowey P; Linker NJ; Slotwiner D; Triedman J; Van Hare GF; Gold MR
    Heart Rhythm; 2017 Jan; 14(1):e41-e44. PubMed ID: 27659101
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical outcome of beta blocker therapy in a patient with long QT syndrome with a critical mutation in the pore of potassium channel].
    Barragán Acea A; Perera Carrillo C; Rayo Gutiérrez M; Marrero Rodríguez F
    Med Clin (Barc); 2004 Apr; 122(14):557. PubMed ID: 15117653
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.